ResApp Health Ltd (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, today announced that it has entered into a binding scheme implementation deed with Pfizer Australia Holdings Pty Ltd (a wholly-owned subsidiary of Pfizer Inc, a global biopharmaceutical company), under which it proposed that Pfizer Inc, will acquire 100% of the shares in ResApp Health by way of a Scheme of Arrangement for A$0.115/share in cash, representing a total equity value of approximately A$100m. ResApp CEO and managing director Tony Keating said ?We are excited by the prospect of this acquisition by Pfizer, a leading biopharmaceutical company that shares our vision and belief that technology can help transform healthcare and improve patients? lives.
Following the announcement, shares of ResApp Ltd traded 22.22% hjgher at $0.11/share.